UK Approves First Once-Daily Weight Loss Pill in Europe

POLICY WIRE — London, UK — The United Kingdom has made a significant advancement in the treatment of obesity by becoming the first European country to approve Orforglipron, a once-daily weight loss pill. The approval was granted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Orforglipron, developed by pharmaceutical company Eli Lilly, is designed to aid weight management in adults with obesity or those who are overweight with at least one weight-related condition. The medication works by mimicking a hormone that helps regulate appetite and food intake.

The clinical trials for Orforglipron demonstrated significant weight loss in participants. According to the study results, individuals taking the highest dose of the medication experienced an average weight loss of 23.5% of their body weight over 72 weeks, compared to 1.7% in the placebo group.

Professor Rachel Batterham, director of the Centre for Obesity Research at University College London, commented on the approval: “This is a major step forward in the fight against obesity. Orforglipron offers a new treatment option for those struggling with weight management, providing hope for millions of people across the UK and potentially beyond.”

The approval process involved rigorous evaluation of the drug’s safety and efficacy. The MHRA reviewed data from multiple clinical trials, ensuring that the benefits of Orforglipron outweigh the risks for patients. Common side effects reported during the trials included nausea, diarrhea, and constipation, though these were generally mild to moderate in severity.

The introduction of Orforglipron is expected to have a substantial impact on public health. Obesity is a growing concern in the UK, with approximately 64% of adults classified as overweight or obese. The condition is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, and certain types of cancer.

Dr. John Wilding, a leading obesity expert and professor of medicine at the University of Liverpool, highlighted the importance of new treatments: “Obesity is a complex disease that requires a multifaceted approach. Medications like Orforglipron, combined with lifestyle changes, can significantly improve health outcomes for patients.”

The approval of Orforglipron in the UK paves the way for potential approval in other European countries. Eli Lilly is expected to submit applications for approval to the European Medicines Agency (EMA) and other regulatory bodies in the coming months.

As the UK leads the way in adopting innovative treatments for obesity, the focus now shifts to ensuring accessibility and affordability for patients. Healthcare providers and policymakers will need to work together to integrate Orforglipron into national health strategies and ensure that it reaches those who need it most.

Reporting by Policy-Wire (PW)